Get the Stockscreener App
1.11
6.72%
-0.08
After Hours:
1.11
Pyxis Oncology Inc stock is traded at $1.11, with a volume of 495.97K.
It is down -6.72% in the last 24 hours and down -26.00% over the past month.
Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.
See More
Previous Close:
$1.19
Open:
$1.21
24h Volume:
495.97K
Relative Volume:
0.51
Market Cap:
$66.01M
Revenue:
-
Net Income/Loss:
$-73.79M
P/E Ratio:
-0.6033
EPS:
-1.84
Net Cash Flow:
$-77.44M
1W Performance:
-9.02%
1M Performance:
-26.00%
6M Performance:
-67.73%
1Y Performance:
-83.16%
1-Day Range:
$1.105
$1.22
1-Week Range:
$1.105
$1.325
52-Week Range:
$1.105
$6.79
Pyxis Oncology Inc Stock (PYXS) Company Profile
Name
Pyxis Oncology Inc
Sector
Industry
Phone
(617) 221-9059
Address
321 HARRISON AVENUE, BOSTON
Compare PYXS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PYXS
Pyxis Oncology Inc
|
1.11 | 66.01M | 0 | -73.79M | -77.44M | -1.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.31 | 124.11B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
684.87 | 74.87B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
622.61 | 37.83B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
243.53 | 31.53B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
111.56 | 26.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Pyxis Oncology Inc Stock (PYXS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-21-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Nov-08-24 | Initiated | Stephens | Overweight |
| Aug-08-24 | Initiated | Stifel | Buy |
| May-07-24 | Resumed | Jefferies | Buy |
| Feb-09-24 | Initiated | BTIG Research | Buy |
| Jan-23-24 | Initiated | Leerink Partners | Outperform |
| Sep-05-23 | Initiated | RBC Capital Mkts | Outperform |
| Nov-02-21 | Initiated | BofA Securities | Neutral |
| Nov-02-21 | Initiated | Credit Suisse | Outperform |
| Nov-02-21 | Initiated | Jefferies | Buy |
View All
Pyxis Oncology Inc Stock (PYXS) Latest News
Pyxis Oncology to Participate at the Leerink Partners Global Healthcare Conference - The Manila Times
Can Pyxis Oncology's CEO Reveal New Cancer Treatment Progress at Upcoming Leerink Conference? - StockTitan
Pyxis Oncology Granted FDA Fast Track Designation for - GlobeNewswire
Pyxis Oncology's US$8.9m Market Cap Fall Books Insider Losses - Simply Wall St
Pyxis Oncology rises on FDA fast track tag for lead asset - MSN
Pyxis Oncology, Inc. Grants Fast Track Designation for PYX-201 Monotherapy in Patients with Recurrent or Metastatic Head and Neck Cancer - Marketscreener.com
FDA fast tracks Pyxis Oncology's head and neck cancer drug By Investing.com - Investing.com Canada
Pyxis Oncology Gets Fast Track Designation For PYX-201 In Head And Neck Cancer - Nasdaq
PYXSPyxis Oncology, Inc. Latest Stock News & Market Updates - StockTitan
FDA fast tracks Pyxis Oncology’s head and neck cancer drug - Investing.com India
Pyxis Oncology stock up on FDA fast track tag (PYXS:NASDAQ) - Seeking Alpha
Pyxis Oncology Announces Fast Track Designation from FDA for PYX-201 in Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma - Nasdaq
Could This FDA Fast Track for Pyxis Oncology's Novel Cancer Drug Accelerate Treatment Options? - StockTitan
Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
Pyxis Oncology (NASDAQ:PYXS) Shares Down 4.7% – Here’s What Happened - Defense World
Pyxis Oncology stock hits 52-week low at $1.23 amid downturn By Investing.com - Investing.com South Africa
Pyxis Oncology stock hits 52-week low at $1.23 amid downturn - Investing.com Canada
Will Pyxis Oncology (NASDAQ:PYXS) Spend Its Cash Wisely? - Yahoo Finance
Pyxis Oncology Inc [PYXS] Investment Appeal on the Rise - Knox Daily
Nothing is Better Than Pyxis Oncology Inc (PYXS) stock at the moment - SETE News
Pyxis Oncology Inc [PYXS] Investment Guide: What You Need to Know - Knox Daily
Financial Health Report: Pyxis Oncology Inc (PYXS)’s Ratios Tell a Tale - The Dwinnex
Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Average Rating of “Moderate Buy” by Analysts - Armenian Reporter
Pyxis Oncology Inc (PYXS) Beta Value: Understanding the Market Risk - The News Heater
Pyxis Oncology Inc [PYXS] stock for 174,364 USD was acquired by Connealy Pamela Ann - Knox Daily
A year in review: Pyxis Oncology Inc (PYXS)’s performance in the last year - US Post News
Financial Metrics Unveiled: Pyxis Oncology Inc (PYXS)’s Key Ratios in the Spotlight - The Dwinnex
BlackRock, Inc. Increases Stake in Pyxis Oncology Inc - GuruFocus.com
Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Pyxis Oncology Initiates New Combination Trial For PYX-201 And Expands Monotherapy Cohorts - Nasdaq
Pyxis Oncology Initiates New PYX-201 Combination Trial and Initiates Cohort Expansions of Ongoing Monotherapy Trial - Marketscreener.com
Pyxis Oncology Initiates New PYX-201 Combination Trial and Initiates Cohort Expansions of ... - The Bakersfield Californian
Major Clinical Advance: Pyxis Teams with Merck for Groundbreaking Cancer Therapy Trial - StockTitan
Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
Pyxis Oncology plummets 38% on preliminary phase 1 data for cancer asset - MSN
Barclays PLC Purchases 46,997 Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS) - Defense World
Pyxis Oncology, Inc. (NASDAQ:PYXS) Holdings Raised by Jane Street Group LLC - Defense World
Pyxis Oncology stock hits 52-week low at $1.49 By Investing.com - Investing.com South Africa
Pyxis Oncology stock hits 52-week low at $1.49 - Investing.com India
Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives $9.43 Average Price Target from Analysts - MarketBeat
Pyxis Oncology, Inc. (NASDAQ:PYXS) Stock Position Raised by Geode Capital Management LLC - Defense World
Barclays PLC Increases Stock Position in Pyxis Oncology, Inc. (NASDAQ:PYXS) - Defense World
State Street Corp Buys 208,344 Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS) - Defense World
Pick Pyxis in head and neck despite pullback on ADC phase I? - BioWorld Online
Pyxis Oncology stock outlook adjusted with focus on ADC program and cost management - Investing.com Nigeria
Pyxis Oncology stock outlook adjusted with focus on ADC program and cost management By Investing.com - Investing.com South Africa
Pyxis Oncology’s (PYXS) “Outperform” Rating Reiterated at Royal Bank of Canada - Defense World
Pyxis Oncology price target lowered to $8 from $10 at RBC Capital - Yahoo Finance
Pyxis Oncology shares target cut, outperform rating on pipeline update By Investing.com - Investing.com Australia
Pyxis Oncology shares target cut, outperform rating on pipeline update - Investing.com
Pyxis Oncology's (PYXS) Buy Rating Reiterated at HC Wainwright - MarketBeat
Pyxis Oncology Inc Stock (PYXS) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.13%
1.23%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):